Methamphetamine Addiction Treatment

There is currently no FDA-approved medication specifically for methamphetamine use disorder. Behavioral therapies — particularly Contingency Management and CBT — are the most evidence-supported approaches.

Methamphetamine causes significant changes to the brain's reward system, and the ability to experience pleasure from ordinary activities can be substantially diminished — a state known as anhedonia — that can persist for months into recovery. Neurological recovery occurs gradually over an extended timeline with sustained abstinence.

Methamphetamine withdrawal is not medically dangerous in the way that alcohol or benzodiazepine withdrawal can be — there is no seizure risk. However, the psychological crash can be severe. Acute symptoms include extreme fatigue, prolonged sleep, depression, intense cravings, and anhedonia. This post-acute phase can last weeks and is a primary driver of early relapse. Medical supervision provides structure and monitoring during this vulnerable period.

The acute withdrawal phase typically lasts one to three weeks. Residential treatment follows for an individualized length, with many clinicians recommending a longer stay for meth use disorder given the prolonged recovery of dopamine function. PHP and IOP step-down programming usually add another 4 to 12 weeks. Our admissions team designs the full continuum at intake and adjusts as your needs evolve.

Yes. We're in-network with HealthSmart, MultiPlan, PMCS, and TriWest, and most major commercial PPO plans — Blue Cross Blue Shield, Aetna, United Healthcare, Anthem, Cigna, Optum, and others — cover medically supervised treatment for methamphetamine use disorder under the Mental Health Parity and Addiction Equity Act. Coverage depends on your specific plan and level of care. Our admissions team verifies your benefits in detail before you commit to anything.

Yes — and this is often necessary. Methamphetamine use disorder frequently co-occurs with depression, anxiety disorders, and in some cases stimulant-induced psychosis that can persist into early recovery. Our integrated dual-diagnosis model addresses both the addiction and any co-occurring mental health conditions within the same program, with the same clinical team.

For most methamphetamine use disorder cases, residential treatment offers a meaningful clinical advantage: removal from the home environment, which typically contains triggers, using peers, and access to the substance. The prolonged nature of meth-related anhedonia — and the high relapse risk during that window — makes immersive residential care the most supported first step. PHP and IOP are appropriate as step-down care following residential stabilization.